

Brief contents

| | | | |
|--|-----|--|--|
| List of boxes | xix | | |
| Acronyms and abbreviations | xxi | | |
| 1 Drugs and drug targets: an overview | 1 | | |
| PART A Drug targets | | | |
| 2 Protein structure and function | 17 | | |
| 3 Enzymes: structure and function | 30 | | |
| 4 Receptors: structure and function | 42 | | |
| 5 Receptors and signal transduction | 58 | | |
| 6 Nucleic acids: structure and function | 71 | | |
| PART B Pharmacodynamics and pharmacokinetics | | | |
| 7 Enzymes as drug targets | 87 | | |
| 8 Receptors as drug targets | 102 | | |
| 9 Nucleic acids as drug targets | 120 | | |
| 10 Miscellaneous drug targets | 135 | | |
| 11 Pharmacokinetics and related topics | 153 | | |
| ■ Case study 1: Statins | 178 | | |
| PART C Drug discovery, design, and development | | | |
| 12 Drug discovery: finding a lead | 189 | | |
| 13 Drug design: optimizing target interactions | 215 | | |
| 14 Drug design: optimizing access to the target | 248 | | |
| 15 Getting the drug to market | 274 | | |
| ■ Case study 2: The design of angiotensin-converting enzyme (ACE) inhibitors | 292 | | |
| ■ Case study 3: Artemisinin and related antimalarial drugs | 299 | | |
| ■ Case study 4: The design of oxamniquine | 305 | | |
| PART D Tools of the trade | | | |
| 16 Combinatorial and parallel synthesis | 313 | | |
| 17 Computers in medicinal chemistry | 337 | | |
| 18 Quantitative structure–activity relationships (QSAR) | 383 | | |
| ■ Case study 5: Design of a thymidylate synthase inhibitor | 407 | | |
| PART E Selected topics in medicinal chemistry | | | |
| 19 Antibacterial agents | 413 | | |
| 20 Antiviral agents | 468 | | |
| 21 Anticancer agents | 514 | | |
| 22 Cholinergics, anticholinergics, and anticholinesterases | 578 | | |
| 23 Drugs acting on the adrenergic nervous system | 609 | | |
| 24 The opioid analgesics | 632 | | |
| 25 Anti-ulcer agents | 659 | | |
| ■ Case study 6: Steroidal anti-inflammatory agents | 689 | | |
| ■ Case Study 7: Current research into antidepressant agents | 700 | | |
| Appendix 1 Essential amino acids | 705 | | |
| Appendix 2 The standard genetic code | 706 | | |
| Appendix 3 Statistical data for quantitative structure–activity relationships (QSAR) | 707 | | |
| Appendix 4 The action of nerves | 711 | | |
| Appendix 5 Microorganisms | 715 | | |
| Appendix 6 Drugs and their trade names | 717 | | |
| Appendix 7 Trade names and drugs | 722 | | |
| Appendix 8 Hydrogen bonding interactions | 728 | | |
| Appendix 9 Drug properties | 730 | | |
| Glossary | 741 | | |
| General further reading | 761 | | |
| Index | 763 | | |

Contents

| | | | |
|---|-----------|--|-----------|
| List of boxes | xix | | |
| Acronyms and abbreviations | xxi | | |
| 1 Drugs and drug targets: an overview | 1 | | |
| 1.1 What is a drug? | 1 | | |
| 1.2 Drug targets | 3 | | |
| 1.2.1 Cell structure | 3 | | |
| 1.2.2 Drug targets at the molecular level | 4 | | |
| 1.3 Intermolecular bonding forces | 5 | | |
| 1.3.1 Electrostatic or ionic bonds | 5 | | |
| 1.3.2 Hydrogen bonds | 6 | | |
| 1.3.3 Van der Waals interactions | 8 | | |
| 1.3.4 Dipole–dipole and ion–dipole interactions | 8 | | |
| 1.3.5 Repulsive interactions | 9 | | |
| 1.3.6 The role of water and hydrophobic interactions | 10 | | |
| 1.4 Pharmacokinetic issues and medicines | 11 | | |
| 1.5 Classification of drugs | 11 | | |
| 1.6 Naming of drugs and medicines | 12 | | |
| | | 3.4 Substrate binding at an active site | 32 |
| | | 3.5 The catalytic role of enzymes | 32 |
| | | 3.5.1 Binding interactions | 32 |
| | | 3.5.2 Acid/base catalysis | 33 |
| | | 3.5.3 Nucleophilic groups | 34 |
| | | 3.5.4 Cofactors | 35 |
| | | 3.5.5 Naming and classification of enzymes | 35 |
| | | 3.5.6 Genetic polymorphism and enzymes | 35 |
| | | 3.6 Regulation of enzymes | 36 |
| | | 3.7 Isozymes | 39 |
| | | 3.8 Enzyme kinetics | 39 |
| | | 3.8.1 The Michaelis-Menton equation | 39 |
| | | 3.8.2 Lineweaver-Burk plots | 40 |
| | | 4 Receptors: structure and function | 42 |
| | | 4.1 Role of the receptor | 42 |
| | | 4.2 Neurotransmitters and hormones | 42 |
| | | 4.3 Receptor types and subtypes | 45 |
| | | 4.4 Receptor activation | 45 |
| | | 4.5 How does the binding site change shape? | 45 |
| | | 4.6 Ion channel receptors | 47 |
| | | 4.6.1 General principles | 47 |
| | | 4.6.2 Structure | 48 |
| | | 4.6.3 Gating | 49 |
| | | 4.6.4 Ligand-gated and voltage-gated ion channels | 49 |
| | | 4.7 G-protein-coupled receptors | 50 |
| | | 4.7.1 General principles | 50 |
| | | 4.7.2 Structure | 51 |
| | | 4.7.3 The rhodopsin-like family of G-protein-coupled receptors | 51 |
| | | 4.7.4 Dimerization of G-coupled receptors | 53 |
| | | 4.8 Kinase-linked receptors | 53 |
| | | 4.8.1 General principles | 53 |
| | | 4.8.2 Structure of tyrosine kinase receptors | 54 |
| | | 4.8.3 Activation mechanism for tyrosine kinase receptors | 54 |
| | | 4.8.4 Tyrosine kinase-linked receptors | 54 |
| | | 4.9 Intracellular receptors | 55 |
| | | 4.10 Regulation of receptor activity | 56 |
| | | 4.11 Genetic polymorphism and receptors | 56 |
| | | 5 Receptors and signal transduction | 58 |
| | | 5.1 Signal transduction pathways for G-protein-coupled receptors | 58 |
| | | 5.1.1 Interaction of the receptor–ligand complex with G-proteins | 58 |
| | | 5.1.2 Signal transduction pathways involving the α -subunit | 59 |
| | | 5.2 Signal transduction involving G-proteins and adenylate cyclase | 60 |
| PART A Drug targets | | | |
| 2 Protein structure and function | 17 | | |
| 2.1 The primary structure of proteins | 17 | | |
| 2.2 The secondary structure of proteins | 18 | | |
| 2.2.1 The α -helix | 18 | | |
| 2.2.2 The β -pleated sheet | 18 | | |
| 2.2.3 The β -turn | 18 | | |
| 2.3 The tertiary structure of proteins | 19 | | |
| 2.3.1 Covalent bonds—disulphide links | 21 | | |
| 2.3.2 Ionic or electrostatic bonds | 21 | | |
| 2.3.3 Hydrogen bonds | 21 | | |
| 2.3.4 Van der Waals and hydrophobic interactions | 22 | | |
| 2.3.5 Relative importance of bonding interactions | 23 | | |
| 2.3.6 Role of the planar peptide bond | 23 | | |
| 2.4 The quaternary structure of proteins | 23 | | |
| 2.5 Translation and post-translational modifications | 25 | | |
| 2.6 Proteomics | 26 | | |
| 2.7 Protein function | 26 | | |
| 2.7.1 Structural proteins | 26 | | |
| 2.7.2 Transport proteins | 27 | | |
| 2.7.3 Enzymes and receptors | 27 | | |
| 2.7.4 Miscellaneous proteins and protein–protein interactions | 28 | | |
| 3 Enzymes: structure and function | 30 | | |
| 3.1 Enzymes as catalysts | 30 | | |
| 3.2 How do enzymes catalyse reactions? | 31 | | |
| 3.3 The active site of an enzyme | 31 | | |

| | | | | | |
|----------|--|-----------|-----------|---|------------|
| 5.2.1 | Activation of adenylate cyclase by the α_s -subunit | 60 | 7.7.3 | Enzyme inhibitors used against the body's own enzymes | 95 |
| 5.2.2 | Activation of protein kinase A | 60 | 7.8 | Enzyme kinetics | 97 |
| 5.2.3 | The G_i -protein | 62 | 7.8.1 | Lineweaver-Burk plots | 97 |
| 5.2.4 | General points about the signalling cascade involving cyclic AMP | 62 | 7.8.2 | Comparison of inhibitors | 99 |
| 5.2.5 | The role of the $\beta\gamma$ -dimer | 63 | | | |
| 5.2.6 | Phosphorylation | 63 | | | |
| 5.3 | Signal transduction involving G-proteins and phospholipase C | 64 | 8 | Receptors as drug targets | 102 |
| 5.3.1 | G-protein effect on phospholipase C | 64 | 8.1 | Introduction | 102 |
| 5.3.2 | Action of the secondary messenger: diacylglycerol | 65 | 8.2 | The design of agonists | 102 |
| 5.3.3 | Action of the secondary messenger: inositol triphosphate | 65 | 8.2.1 | Binding groups | 102 |
| 5.3.4 | Re-synthesis of phosphatidylinositol diphosphate | 65 | 8.2.2 | Position of the binding groups | 104 |
| 5.4 | Signal transduction involving kinase-linked receptors | 66 | 8.2.3 | Size and shape | 105 |
| 5.4.1 | Activation of signalling proteins and enzymes | 66 | 8.2.4 | Other design strategies | 105 |
| 5.4.2 | Small G-proteins | 67 | 8.2.5 | Pharmacodynamics and pharmacokinetics | 105 |
| 5.4.3 | Activation of guanylate cyclase by kinase receptors | 68 | 8.2.6 | Examples of agonists | 106 |
| | | | 8.2.7 | Allosteric modulators | 106 |
| | | | 8.3 | The design of antagonists | 107 |
| 6 | Nucleic acids: structure and function | 71 | 8.3.1 | Antagonists acting at the binding site | 107 |
| 6.1 | Structure of DNA | 71 | 8.3.2 | Antagonists acting out with the binding site | 110 |
| 6.1.1 | The primary structure of DNA | 71 | 8.4 | Partial agonists | 111 |
| 6.1.2 | The secondary structure of DNA | 71 | 8.5 | Inverse agonists | 112 |
| 6.1.3 | The tertiary structure of DNA | 74 | 8.6 | Desensitization and sensitization | 112 |
| 6.1.4 | Chromatins | 76 | 8.7 | Tolerance and dependence | 114 |
| 6.1.5 | Genetic polymorphism and personalized medicine | 76 | 8.8 | Receptor types and subtypes | 114 |
| 6.2 | Ribonucleic acid and protein synthesis | 76 | 8.9 | Affinity, efficacy, and potency | 116 |
| 6.2.1 | Structure of RNA | 76 | 9 | Nucleic acids as drug targets | 120 |
| 6.2.2 | Transcription and translation | 77 | 9.1 | Intercalating drugs acting on DNA | 120 |
| 6.2.3 | Small nuclear RNA | 79 | 9.2 | Topoisomerase poisons: non-intercalating | 121 |
| 6.3 | Genetic illnesses | 79 | 9.3 | Alkylating and metallating agents | 123 |
| 6.4 | Molecular biology and genetic engineering | 81 | 9.3.1 | Nitrogen mustards | 124 |
| | | | 9.3.2 | Nitrosoureas | 124 |
| | | | 9.3.3 | Busulfan | 124 |
| | | | 9.3.4 | Cisplatin | 125 |
| | | | 9.3.5 | Dacarbazine and procarbazine | 126 |
| | | | 9.3.6 | Mitomycin C | 127 |
| | | | 9.4 | Chain cutters | 128 |
| | | | 9.5 | Chain terminators | 129 |
| | | | 9.6 | Control of gene transcription | 130 |
| | | | 9.7 | Agents that act on RNA | 131 |
| | | | 9.7.1 | Agents that bind to ribosomes | 131 |
| | | | 9.7.2 | Antisense therapy | 131 |
| | | | 10 | Miscellaneous drug targets | 135 |
| | | | 10.1 | Transport proteins as drug targets | 135 |
| | | | 10.2 | Structural proteins as drug targets | 135 |
| | | | 10.2.1 | Viral structural proteins as drug targets | 135 |
| | | | 10.2.2 | Tubulin as a drug target | 135 |
| | | | 10.3 | Biosynthetic building blocks as drug targets | 138 |
| | | | 10.4 | Biosynthetic processes as drug targets: chain terminators | 139 |
| | | | 10.5 | Protein-protein interactions | 139 |

PART B Pharmacodynamics and pharmacokinetics

7 Enzymes as drug targets

87

| | | |
|-------|---|----|
| 7.1 | Inhibitors acting at the active site of an enzyme | 87 |
| 7.1.1 | Reversible inhibitors | 87 |
| 7.1.2 | Irreversible inhibitors | 89 |
| 7.2 | Inhibitors acting at allosteric binding sites | 89 |
| 7.3 | Uncompetitive and non-competitive inhibitors | 90 |
| 7.4 | Transition-state analogues: renin inhibitors | 90 |
| 7.5 | Suicide substrates | 92 |
| 7.6 | Isozyme selectivity of inhibitors | 93 |
| 7.7 | Medicinal uses of enzyme inhibitors | 93 |
| 7.7.1 | Enzyme inhibitors used against microorganisms | 93 |
| 7.7.2 | Enzyme inhibitors used against viruses | 95 |

| | | | | | |
|---|---|------------|-----------|--|------------|
| 10.6 | Lipids as drug targets | 143 | 12.2 | Choosing a drug target | 189 |
| 10.6.1 | ‘Tunnelling molecules’ | 143 | 12.2.1 | Drug targets | 189 |
| 10.6.2 | Ion carriers | 146 | 12.2.2 | Discovering drug targets | 189 |
| 10.6.3 | Tethers and anchors | 147 | 12.2.3 | Target specificity and selectivity between species | 191 |
| 10.7 | Carbohydrates as drug targets | 148 | 12.2.4 | Target specificity and selectivity within the body | 191 |
| 10.7.1 | Glycomics | 148 | 12.2.5 | Targeting drugs to specific organs and tissues | 192 |
| 10.7.2 | Antigens and antibodies | 149 | 12.2.6 | Pitfalls | 192 |
| 10.7.3 | Cyclodextrins | 151 | 12.2.7 | Multi-target drugs | 193 |
| 11 | Pharmacokinetics and related topics | 153 | 12.3 | Identifying a bioassay | 195 |
| 11.1 | The three phases of drug action | 153 | 12.3.1 | Choice of bioassay | 195 |
| 11.2 | A typical journey for an orally active drug | 153 | 12.3.2 | <i>In vitro</i> tests | 195 |
| 11.3 | Drug absorption | 154 | 12.3.3 | <i>In vivo</i> tests | 195 |
| 11.4 | Drug distribution | 156 | 12.3.4 | Test validity | 196 |
| 11.4.1 | Distribution around the blood supply | 156 | 12.3.5 | High-throughput screening | 196 |
| 11.4.2 | Distribution to tissues | 156 | 12.3.6 | Screening by nuclear magnetic resonance | 197 |
| 11.4.3 | Distribution to cells | 156 | 12.3.7 | Affinity screening | 197 |
| 11.4.4 | Other distribution factors | 156 | 12.3.8 | Surface plasmon resonance | 197 |
| 11.4.5 | Blood–brain barrier | 156 | 12.3.9 | Scintillation proximity assay | 198 |
| 11.4.6 | Placental barrier | 157 | 12.3.10 | Isothermal titration calorimetry | 198 |
| 11.4.7 | Drug–drug interactions | 157 | 12.3.11 | Virtual screening | 198 |
| 11.5 | Drug metabolism | 157 | 12.4 | Finding a lead compound | 199 |
| 11.5.1 | Phase I and phase II metabolism | 158 | 12.4.1 | Screening of natural products | 199 |
| 11.5.2 | Phase I transformations catalysed by cytochrome P450 enzymes | 158 | 12.4.2 | Medical folklore | 202 |
| 11.5.3 | Phase I transformations catalysed by flavin-containing monooxygenases | 160 | 12.4.3 | Screening synthetic compound ‘libraries’ | 202 |
| 11.5.4 | Phase I transformations catalysed by other enzymes | 160 | 12.4.4 | Existing drugs | 203 |
| 11.5.5 | Phase II transformations | 160 | 12.4.5 | Starting from the natural ligand or modulator | 204 |
| 11.5.6 | Metabolic stability | 163 | 12.4.6 | Combinatorial and parallel synthesis | 207 |
| 11.5.7 | The first pass effect | 167 | 12.4.7 | Computer-aided design of lead compounds | 207 |
| 11.6 | Drug excretion | 167 | 12.4.8 | Serendipity and the prepared mind | 207 |
| 11.7 | Drug administration | 168 | 12.4.9 | Computerized searching of structural databases | 209 |
| 11.7.1 | Oral administration | 169 | 12.4.10 | Fragment-based lead discovery | 209 |
| 11.7.2 | Absorption through mucous membranes | 169 | 12.4.11 | Properties of lead compounds | 211 |
| 11.7.3 | Rectal administration | 169 | 12.5 | Isolation and purification | 212 |
| 11.7.4 | Topical administration | 169 | 12.6 | Structure determination | 212 |
| 11.7.5 | Inhalation | 170 | 12.7 | Herbal medicine | 212 |
| 11.7.6 | Injection | 170 | 13 | Drug design: optimizing target interactions | 215 |
| 11.7.7 | Implants | 171 | 13.1 | Structure–activity relationships | 215 |
| 11.8 | Drug dosing | 171 | 13.1.1 | Binding role of alcohols and phenols | 216 |
| 11.8.1 | Drug half-life | 172 | 13.1.2 | Binding role of aromatic rings | 217 |
| 11.8.2 | Steady state concentration | 172 | 13.1.3 | Binding role of alkenes | 218 |
| 11.8.3 | Drug tolerance | 173 | 13.1.4 | The binding role of ketones and aldehydes | 218 |
| 11.8.4 | Bioavailability | 173 | 13.1.5 | Binding role of amines | 218 |
| 11.9 | Formulation | 173 | 13.1.6 | Binding role of amides | 219 |
| 11.10 | Drug delivery | 174 | 13.1.7 | Binding role of quaternary ammonium salts | 221 |
| ■ | Case study 1: Statins | 178 | 13.1.8 | Binding role of carboxylic acids | 221 |
| PART C Drug discovery, design, and development | | | | | |
| 12. | Drug discovery: finding a lead | 189 | 13.1.9 | Binding role of esters | 222 |
| 12.1 | Choosing a disease | 189 | 13.1.10 | Binding role of alkyl and aryl halides | 222 |
| | | | 13.1.11 | Binding role of thiols and ethers | 223 |
| | | | 13.1.12 | Binding role of other functional groups | 223 |
| | | | 13.1.13 | Binding role of alkyl groups and the carbon skeleton | 223 |
| | | | 13.1.14 | Binding role of heterocycles | 223 |
| | | | 13.1.15 | Isosteres | 225 |

| | | | | | |
|-----------|--|------------|-----------|---|------------|
| 16.3 | Planning and designing a compound library | 318 | 17.11.1 | X-ray crystallography | 355 |
| 16.3.1 | 'Spider-like' scaffolds | 318 | 17.11.2 | Structural comparison of active compounds | 355 |
| 16.3.2 | Designing 'drug-like' molecules | 318 | 17.11.3 | Automatic identification of pharmacophores | 355 |
| 16.3.3 | Synthesis of scaffolds | 319 | 17.12 | Docking procedures | 356 |
| 16.3.4 | Substituent variation | 319 | 17.12.1 | Manual docking | 356 |
| 16.3.5 | Designing compound libraries for lead optimization | 319 | 17.12.2 | Automatic docking | 357 |
| 16.3.6 | Computer-designed libraries | 320 | 17.12.3 | Defining the molecular surface of a binding site | 357 |
| 16.4 | Testing for activity | 321 | 17.12.4 | Rigid docking by shape complementarity | 358 |
| 16.4.1 | High-throughput screening | 321 | 17.12.5 | The use of grids in docking programs | 361 |
| 16.4.2 | Screening 'on bead' or 'off bead' | 321 | 17.12.6 | Rigid docking by matching hydrogen bonding groups | 361 |
| 16.5 | Parallel synthesis | 322 | 17.12.7 | Rigid docking of flexible ligands: the FLOG program | 361 |
| 16.5.1 | Solid phase extraction | 323 | 17.12.8 | Docking of flexible ligands: anchor and grow programs | 362 |
| 16.5.2 | The use of resins in solution phase organic synthesis (SPOS) | 324 | 17.12.9 | Docking of flexible ligands: simulated annealing and genetic algorithms | 366 |
| 16.5.3 | Reagents attached to solid support: catch and release | 324 | 17.13 | Automated screening of databases for lead compounds | 366 |
| 16.5.4 | Microwave technology | 325 | 17.14 | Protein mapping | 366 |
| 16.5.5 | Microfluidics in parallel synthesis | 325 | 17.14.1 | Constructing a model protein: homology modelling | 367 |
| 16.6 | Combinatorial synthesis | 328 | 17.14.2 | Constructing a binding site: hypothetical pseudoreceptors | 368 |
| 16.6.1 | The mix and split method in combinatorial synthesis | 328 | 17.15 | <i>De novo</i> drug design | 370 |
| 16.6.2 | Structure determination of the active compound(s) | 329 | 17.15.1 | General principles of <i>de novo</i> drug design | 370 |
| 16.6.3 | Dynamic combinatorial synthesis | 331 | 17.15.2 | Automated <i>de novo</i> drug design | 371 |
| 17 | Computers in medicinal chemistry | 337 | 17.16 | Planning compound libraries | 379 |
| 17.1 | Molecular and quantum mechanics | 337 | 17.17 | Database handling | 379 |
| 17.1.1 | Molecular mechanics | 337 | 18 | Quantitative structure–activity relationships (QSAR) | 383 |
| 17.1.2 | Quantum mechanics | 337 | 18.1 | Graphs and equations | 383 |
| 17.1.3 | Choice of method | 338 | 18.2 | Physicochemical properties | 384 |
| 17.2 | Drawing chemical structures | 338 | 18.2.1 | Hydrophobicity | 385 |
| 17.3 | Three-dimensional structures | 338 | 18.2.2 | Electronic effects | 388 |
| 17.4 | Energy minimization | 339 | 18.2.3 | Steric factors | 390 |
| 17.5 | Viewing 3D molecules | 339 | 18.2.4 | Other physicochemical parameters | 392 |
| 17.6 | Molecular dimensions | 341 | 18.3 | Hansch equation | 392 |
| 17.7 | Molecular properties | 341 | 18.4 | The Craig plot | 392 |
| 17.7.1 | Partial charges | 341 | 18.5 | The Topliss scheme | 394 |
| 17.7.2 | Molecular electrostatic potentials | 342 | 18.6 | Bioisosteres | 397 |
| 17.7.3 | Molecular orbitals | 343 | 18.7 | The Free-Wilson approach | 397 |
| 17.7.4 | Spectroscopic transitions | 343 | 18.8 | Planning a QSAR study | 397 |
| 17.7.5 | The use of grids in measuring molecular properties | 344 | 18.9 | Case study | 398 |
| 17.8 | Conformational analysis | 346 | 18.10 | Three-dimensional QSAR | 401 |
| 17.8.1 | Local and global energy minima | 346 | 18.10.1 | Defining steric and electrostatic fields | 401 |
| 17.8.2 | Molecular dynamics | 346 | 18.10.2 | Relating shape and electronic distribution to biological activity | 402 |
| 17.8.3 | Stepwise bond rotation | 347 | 18.10.3 | Advantages of CoMFA over traditional QSAR | 403 |
| 17.8.4 | Monte Carlo and the Metropolis method | 348 | | | |
| 17.8.5 | Genetic and evolutionary algorithms | 350 | | | |
| 17.9 | Structure comparisons and overlays | 351 | | | |
| 17.10 | Identifying the active conformation | 352 | | | |
| 17.10.1 | X-ray crystallography | 352 | | | |
| 17.10.2 | Comparison of rigid and non-rigid ligands | 353 | | | |
| 17.11 | 3D pharmacophore identification | 354 | | | |

| | | | | | |
|--|--|------------|-----------|---|------------|
| 18.10.4 | Potential problems of CoMFA | 403 | 20 | Antiviral agents | 468 |
| 18.10.5 | Other 3D QSAR methods | 404 | 20.1 | Viruses and viral diseases | 468 |
| 18.10.6 | Case study: inhibitors of tubulin polymerization | 404 | 20.2 | Structure of viruses | 468 |
| ■ | Case study 5: Design of a thymidylate synthase inhibitor | 407 | 20.3 | Life cycle of viruses | 469 |
| PART E Selected topics in medicinal chemistry | | | | | |
| 19 | Antibacterial agents | 413 | 20.4 | Vaccination | 470 |
| 19.1 | History of antibacterial agents | 413 | 20.5 | Antiviral drugs: general principles | 471 |
| 19.2 | The bacterial cell | 415 | 20.6 | Antiviral drugs used against DNA viruses | 472 |
| 19.3 | Mechanisms of antibacterial action | 415 | 20.6.1 | Inhibitors of viral DNA polymerase | 472 |
| 19.4 | Antibacterial agents which act against cell metabolism (antimetabolites) | 416 | 20.6.2 | Inhibitors of tubulin polymerization | 474 |
| 19.4.1 | Sulphonamides | 416 | 20.6.3 | Antisense therapy | 475 |
| 19.4.2 | Examples of other antimetabolites | 420 | 20.7 | Antiviral drugs acting against RNA viruses: HIV | 476 |
| 19.5 | Antibacterial agents which inhibit cell wall synthesis | 421 | 20.7.1 | Structure and life cycle of HIV | 476 |
| 19.5.1 | Penicillins | 421 | 20.7.2 | Antiviral therapy against HIV | 477 |
| 19.5.2 | Cephalosporins | 436 | 20.7.3 | Inhibitors of viral reverse transcriptase | 478 |
| 19.5.3 | Other β -lactam antibiotics | 442 | 20.7.4 | Protease inhibitors | 480 |
| 19.5.4 | β -Lactamase inhibitors | 444 | 20.7.5 | Inhibitors of other targets | 493 |
| 19.5.5 | Other drugs which act on bacterial cell wall biosynthesis | 445 | 20.8 | Antiviral drugs acting against RNA viruses: flu virus | 496 |
| 19.6 | Antibacterial agents which act on the plasma membrane structure | 450 | 20.8.1 | Structure and life cycle of the influenza virus | 496 |
| 19.6.1 | Valinomycin and gramicidin A | 450 | 20.8.2 | Ion channel disrupters: adamantanes | 498 |
| 19.6.2 | Polymyxin B | 450 | 20.8.3 | Neuraminidase inhibitors | 498 |
| 19.6.3 | Killer nanotubes | 450 | 20.9 | Antiviral drugs acting against RNA viruses: cold virus | 507 |
| 19.6.4 | Cyclic lipopeptides | 451 | 20.10 | Antiviral drugs acting against RNA viruses: hepatitis C | 508 |
| 19.7 | Antibacterial agents which impair protein synthesis: translation | 452 | 20.11 | Broad-spectrum antiviral agents | 510 |
| 19.7.1 | Aminoglycosides | 452 | 20.11.1 | Agents acting against cytidine triphosphate synthetase | 510 |
| 19.7.2 | Tetracyclines | 454 | 20.11.2 | Agents acting against S-adenosylhomocysteine hydrolase | 510 |
| 19.7.3 | Chloramphenicol | 455 | 20.11.3 | Ribavirin | 510 |
| 19.7.4 | Macrolides | 455 | 20.11.4 | Interferons | 510 |
| 19.7.5 | Lincosamides | 456 | 20.11.5 | Antibodies and ribozymes | 511 |
| 19.7.6 | Streptogramins | 456 | 20.12 | Bioterrorism and smallpox | 511 |
| 19.7.7 | Oxazolidinones | 456 | 21 | Anticancer agents | 514 |
| 19.8 | Agents that act on nucleic acid transcription and replication | 457 | 21.1 | Cancer: an introduction | 514 |
| 19.8.1 | Quinolones and fluoroquinolones | 457 | 21.1.1 | Definitions | 514 |
| 19.8.2 | Aminoacridines | 459 | 21.1.2 | Causes of cancer | 514 |
| 19.8.3 | Rifamycins | 460 | 21.1.3 | Genetic faults leading to cancer: proto-oncogenes and oncogenes | 514 |
| 19.8.4 | Nitroimidazoles and nitrofurantoin | 460 | 21.1.4 | Abnormal signalling pathways | 515 |
| 19.8.5 | Inhibitors of bacterial RNA polymerase | 461 | 21.1.5 | Insensitivity to growth-inhibitory signals | 516 |
| 19.9 | Miscellaneous agents | 461 | 21.1.6 | Abnormalities in cell cycle regulation | 516 |
| 19.10 | Drug resistance | 462 | 21.1.7 | Apoptosis and the p53 protein | 517 |
| 19.10.1 | Drug resistance by mutation | 462 | 21.1.8 | Telomeres | 519 |
| 19.10.2 | Drug resistance by genetic transfer | 463 | 21.1.9 | Angiogenesis | 519 |
| 19.10.3 | Other factors affecting drug resistance | 463 | 21.1.10 | Tissue invasion and metastasis | 521 |
| 19.10.4 | The way ahead | 463 | 21.1.11 | Treatment of cancer | 521 |
| | | | 21.1.12 | Resistance | 523 |
| | | | 21.2 | Drugs acting directly on nucleic acids | 524 |

| | | | | | |
|--------|---|-----|---|--|-----|
| 21.2.1 | Intercalating agents | 524 | 22 Cholinergics, anticholinergics, and anticholinesterases | 578 | |
| 21.2.2 | Non-intercalating agents which inhibit the action of topoisomerase enzymes on DNA | 526 | 22.1 | The peripheral nervous system | 578 |
| 21.2.3 | Alkylating and metallating agents | 526 | 22.2 | Motor nerves of the PNS | 578 |
| 21.2.4 | Chain cutters | 529 | 22.2.1 | The somatic motor nervous system | 579 |
| 21.2.5 | Antisense therapy | 529 | 22.2.2 | The autonomic motor nervous system | 579 |
| 21.3 | Drugs acting on enzymes: antimetabolites | 531 | 22.2.3 | The enteric system | 580 |
| 21.3.1 | Dihydrofolate reductase inhibitors | 531 | 22.2.4 | Defects in motor nerve transmission | 580 |
| 21.3.2 | Inhibitors of thymidylate synthase | 532 | 22.3 | The cholinergic system | 580 |
| 21.3.3 | Inhibitors of ribonucleotide reductase | 534 | 22.3.1 | The cholinergic signalling system | 580 |
| 21.3.4 | Inhibitors of adenosine deaminase | 535 | 22.3.2 | Presynaptic control systems | 580 |
| 21.3.5 | Inhibitors of DNA polymerases | 535 | 22.3.3 | Co-transmitters | 581 |
| 21.3.6 | Purine antagonists | 536 | 22.4 | Agonists at the cholinergic receptor | 582 |
| 21.3.7 | Inhibitors of poly ADP ribose polymerase | 536 | 22.5 | Acetylcholine: structure, structure–activity relationships, and receptor binding | 583 |
| 21.4 | Hormone-based therapies | 536 | 22.6 | The instability of acetylcholine | 584 |
| 21.4.1 | Glucocorticoids, estrogens, progestins, and androgens | 537 | 22.7 | Design of acetylcholine analogues | 585 |
| 21.4.2 | Luteinizing hormone-releasing hormone agonists | 537 | 22.7.1 | Steric shields | 585 |
| 21.4.3 | Anti-estrogens | 538 | 22.7.2 | Electronic effects | 586 |
| 21.4.4 | Anti-androgens | 538 | 22.7.3 | Combining steric and electronic effects | 586 |
| 21.4.5 | Aromatase inhibitors | 538 | 22.8 | Clinical uses for cholinergic agonists | 586 |
| 21.5 | Drugs acting on structural proteins | 539 | 22.8.1 | Muscarinic agonists | 586 |
| 21.5.1 | Agents which inhibit tubulin polymerization | 540 | 22.8.2 | Nicotinic agonists | 586 |
| 21.5.2 | Agents which inhibit tubulin depolymerization | 542 | 22.9 | Antagonists of the muscarinic cholinergic receptor | 587 |
| 21.6 | Inhibitors of signalling pathways | 544 | 22.9.1 | Actions and uses of muscarinic antagonists | 587 |
| 21.6.1 | Inhibition of farnesyl transferase and the Ras protein | 544 | 22.9.2 | Muscarinic antagonists | 588 |
| 21.6.2 | Protein kinase inhibitors | 547 | 22.10 | Antagonists of the nicotinic cholinergic receptor | 590 |
| 21.7 | Miscellaneous enzyme inhibitors | 561 | 22.10.1 | Applications of nicotinic antagonists | 590 |
| 21.7.1 | Matrix metalloproteinase inhibitors | 561 | 22.10.2 | Nicotinic antagonists | 591 |
| 21.7.2 | Proteasome inhibitors | 563 | 22.11 | Receptor structures | 594 |
| 21.7.3 | Histone deacetylase inhibitors | 564 | 22.12 | Anticholinesterases and acetylcholinesterase | 595 |
| 21.7.4 | Other enzyme targets | 564 | 22.12.1 | Effect of anticholinesterases | 595 |
| 21.8 | Miscellaneous anticancer agents | 564 | 22.12.2 | Structure of the acetylcholinesterase enzyme | 595 |
| 21.8.1 | Synthetic agents | 565 | 22.12.3 | The active site of acetylcholinesterase | 596 |
| 21.8.2 | Natural products | 566 | 22.13 | Anticholinesterase drugs | 597 |
| 21.8.3 | Protein therapy | 566 | 22.13.1 | Carbamates | 598 |
| 21.8.4 | Modulation of transcription factor–co-activator interactions | 567 | 22.13.2 | Organophosphorus compounds | 600 |
| 21.9 | Antibodies, antibody conjugates, and gene therapy | 568 | 22.14 | Pralidoxime: an organophosphate antidote | 602 |
| 21.9.1 | Monoclonal antibodies | 568 | 22.15 | Anticholinesterases as ‘smart drugs’ | 603 |
| 21.9.2 | Antibody–drug conjugates | 568 | 22.15.1 | Acetylcholinesterase inhibitors | 603 |
| 21.9.3 | Antibody-directed enzyme prodrug therapy (ADEPT) | 570 | 22.15.2 | Dual-action agents acting on the acetylcholinesterase enzyme | 604 |
| 21.9.4 | Antibody-directed abzyme prodrug therapy (ADAPT) | 572 | 22.15.3 | Multi-targeted agents acting on the acetylcholinesterase enzyme and the muscarinic M ₂ receptor | 606 |
| 21.9.5 | Gene-directed enzyme prodrug therapy (GDEPT) | 572 | 23 Drugs acting on the adrenergic nervous system | 609 | |
| 21.9.6 | Other forms of gene therapy | 573 | 23.1 | The adrenergic nervous system | 609 |
| 21.10 | Photodynamic therapy | 573 | | | |

| | | | | | |
|-----------|--|------------|------------|---|------------|
| 23.1.1 | Peripheral nervous system | 609 | 24.7 | Agonists and antagonists | 647 |
| 23.1.2 | Central nervous system | 609 | 24.8 | Endogenous opioid peptides and opioids | 649 |
| 23.2 | Adrenergic receptors | 609 | 24.8.1 | Endogenous opioid peptides | 649 |
| 23.2.1 | Types of adrenergic receptor | 609 | 24.8.2 | Analogues of enkephalins and δ -selective opioids | 650 |
| 23.2.2 | Distribution of receptors | 610 | 24.8.3 | Binding theories for enkephalins | 652 |
| 23.3 | Endogenous agonists for the adrenergic receptors | 611 | 24.8.4 | Inhibitors of peptidases | 653 |
| 23.4 | Biosynthesis of catecholamines | 611 | 24.8.5 | Endogenous morphine | 653 |
| 23.5 | Metabolism of catecholamines | 612 | 24.9 | The future | 653 |
| 23.6 | Neurotransmission | 612 | 24.9.1 | The message–address concept | 653 |
| 23.6.1 | The neurotransmission process | 612 | 24.9.2 | Receptor dimers | 654 |
| 23.6.2 | Co-transmitters | 612 | 24.9.3 | Selective opioid agonists versus multi-targeted opioids | 655 |
| 23.6.3 | Presynaptic receptors and control | 613 | 24.9.4 | Peripheral-acting opioids | 655 |
| 23.7 | Drug targets | 614 | 24.10 | Case study: design of nalfurafine | 655 |
| 23.8 | The adrenergic binding site | 614 | 25 | Anti-ulcer agents | 659 |
| 23.9 | Structure–activity relationships | 615 | 25.1 | Peptic ulcers | 659 |
| 23.9.1 | Important binding groups on catecholamines | 615 | 25.1.1 | Definition | 659 |
| 23.9.2 | Selectivity for α - versus β -adrenoceptors | 616 | 25.1.2 | Causes | 659 |
| 23.10 | Adrenergic agonists | 616 | 25.1.3 | Treatment | 659 |
| 23.10.1 | General adrenergic agonists | 616 | 25.1.4 | Gastric acid release | 659 |
| 23.10.2 | α_1 -, α_2 -, β_1 -, and β_3 -Agonists | 617 | 25.2 | H ₂ antagonists | 660 |
| 23.10.3 | β_2 -Agonists and the treatment of asthma | 618 | 25.2.1 | Histamine and histamine receptors | 661 |
| 23.11 | Adrenergic receptor antagonists | 620 | 25.2.2 | Searching for a lead | 662 |
| 23.11.1 | General α -/ β -blockers | 620 | 25.2.3 | Developing the lead: a chelation bonding theory | 665 |
| 23.11.2 | α -Blockers | 620 | 25.2.4 | From partial agonist to antagonist: the development of burimamide | 665 |
| 23.11.3 | β -Blockers as cardiovascular drugs | 621 | 25.2.5 | Development of metiamide | 667 |
| 23.12 | Other drugs affecting adrenergic transmission | 626 | 25.2.6 | Development of cimetidine | 670 |
| 23.12.1 | Drugs that affect the biosynthesis of adrenergics | 626 | 25.2.7 | Cimetidine | 671 |
| 23.12.2 | Drugs inhibiting the uptake of noradrenaline into storage vesicles | 627 | 25.2.8 | Further studies of cimetidine analogues | 673 |
| 23.12.3 | Release of noradrenaline from storage vesicles | 627 | 25.2.9 | Further H ₂ antagonists | 676 |
| 23.12.4 | Reuptake inhibitors of noradrenaline into presynaptic neurons | 627 | 25.2.10 | Comparison of H ₁ and H ₂ antagonists | 678 |
| 23.12.5 | Inhibition of metabolic enzymes | 629 | 25.2.11 | H ₂ -receptors and H ₂ antagonists | 679 |
| 24 | The opioid analgesics | 632 | 25.3 | Proton pump inhibitors | 679 |
| 24.1 | History of opium | 632 | 25.3.1 | Parietal cells and the proton pump | 679 |
| 24.2 | The active principle: morphine | 632 | 25.3.2 | Proton pump inhibitors | 680 |
| 24.2.1 | Isolation of morphine | 632 | 25.3.3 | Mechanism of inhibition | 681 |
| 24.2.2 | Structure and properties | 633 | 25.3.4 | Metabolism of proton pump inhibitors | 682 |
| 24.3 | Structure–activity relationships | 633 | 25.3.5 | Design of omeprazole and esomeprazole | 682 |
| 24.4 | The molecular target for morphine: opioid receptors | 635 | 25.3.6 | Other proton pump inhibitors | 684 |
| 24.5 | Morphine: pharmacodynamics and pharmacokinetics | 636 | 25.4 | <i>Helicobacter pylori</i> and the use of antibacterial agents | 685 |
| 24.6 | Morphine analogues | 638 | 25.4.1 | Discovery of <i>Helicobacter pylori</i> | 685 |
| 24.6.1 | Variation of substituents | 638 | 25.4.2 | Treatment | 685 |
| 24.6.2 | Drug extension | 638 | 25.5 | Traditional and herbal medicines | 687 |
| 24.6.3 | Simplification or drug dissection | 640 | ■ | Case study 6: Steroidal anti-inflammatory agents | 689 |
| 24.6.4 | Rigidification | 644 | ■ | Case Study 7: Current research into antidepressant agents | 700 |
| | | | APPENDIX 1 | Essential amino acids | 705 |
| | | | APPENDIX 2 | The standard genetic code | 706 |

xviii Contents

| | | | |
|---|-----|--|-----|
| APPENDIX 3 Statistical data for quantitative structure–activity relationships (QSAR) | 707 | APPENDIX 8 Hydrogen bonding interactions | 728 |
| APPENDIX 4 The action of nerves | 711 | APPENDIX 9 Drug properties | 730 |
| APPENDIX 5 Microorganisms | 715 | GLOSSARY | 741 |
| APPENDIX 6 Drugs and their trade names | 717 | GENERAL FURTHER READING | 761 |
| APPENDIX 7 Trade names and drugs | 722 | INDEX | 763 |